4C Group AB (”4C” eller ”Bolaget”) är en ledande leverantör av mjukvara och utbildning avseende orga...
Redeye comments on Embracer Groups' somewhat delayed partnership and licensing deals, which now are ...
Prostatype Genomics has proposed a SEK 34.3m funding (new issue of shares with preferential rights f...
Rörelsemarginalen pressades under Q4 och bolaget står inför ökade investeringar.
Arcede har levererat viktiga framsteg kring kandidaten RCD405 mot primärt lungsjukdomen KOL.
Redeye thinks that with the rights issue completed, Smart Eye is now set to start its revenue accele...
Redeye initiates coverage of Klaria Pharma Holding AB, a Swedish biotech company, utilising its tran...
Redeye comments on Better Collective’s capital markets day giving our key takes on the event where t...
Redeye provides a research update on Lipum following the Q4 report published by the company earlier ...
Redeye updates its view on Flexion Mobile following its strong Q4 2022 report released on March 22.
Q-linea is in the early stage of its targeted European launch strategy.
Redeye thinks the presented study of global and European DMS adoption supports Smart Eye becoming ca...
Rovio’s Board of Directors today confirmed that the preliminary discussions with Playtika in connect...
Redeye is encouraged to learn that Faron has received positive FDA feedback and recommendations for ...
CoinShares International (CS) rapporterade en måttlig EBITDA-förlust på 6,5 miljoner GBP för FY22 (j...
Eevia Health Plc (publ) (”Eevia Health”, “Eevia” or “the Company”) is at a stage where the Company i...
2022 EBIT impacted by bad debt provisions of SEK 34m The provision relates to its Italian distributo...
Redeye comments on Flexion Mobiles Q4 2022 report. Strong revenue growth of 108% y/y, despite a chal...
Completes a SEK 52.6m directed share issue 4.5% EPS dilution, 4.
AcuCort AB (”AcuCort” eller ”Bolaget”) har erhållit godkännande inom samtliga nordiska länder för Bo...
